Patterns of First Relapse and Outcome in Patients with Locally Advanced Cervical Cancer After Radiochemotherapy: A Single Institutional Experience

  • Ajay Sasidharan
  • Umesh M. MahantshettyEmail author
  • Lavanya Gurram
  • Supriya Chopra
  • Reena Engineer
  • Amita Maheshwari
  • Sudeep Gupta
  • Kedar Deodhar
  • Venkatesh Rangarajan
  • Meenakshi Thakur
  • Shyam Kishore Shrivastava
Original Article



Radiochemotherapy followed by brachytherapy is the standard treatment in locally advanced cervical cancer. The aim of this study was to evaluate the patterns of first relapse, the treatment given and its outcome.


This is a retrospective analysis of electronic records of locally advanced cervical cancer patients treated in prospective trials from 2003 to 2014.


Out of 1388 patients, relapse was seen in 316 (23%). Relapse was seen as—pelvic: 105 (7.6%), distant: 136 (10%), and both: 75 (5.4%). Local, regional, paraaortic and systemic relapses were seen in 148 (10.8%), 65 (4.7%), 102 (7.4%) and 163 (11.8%) patients, respectively. Post-relapse, 201/316 (63.6%) received palliative care alone. Treatment in the form of concurrent or sequential chemo-radiotherapy, surgery, stereotactic body radiotherapy and reirradiation using brachytherapy was received by 15 (4.7%), 7 (2.2%), 1 (0.3%) and 1(0.3%) patients, respectively; 65 (20.6%) received palliative chemotherapy, and 28 (8.9%) received palliative radiotherapy. Median post-relapse survival was 7 months (95% CI 5.9–8.1); and in those who received treatment versus supportive care was 10 (95% CI 7.0–13.0) versus 5 (95% CI 3.9–6.1) months (p < 0.001). The proportion of patients with > 1-year post-relapse survival was 85.7% in surgery, 66.7% in concurrent or sequential chemotherapy plus radiation, 32.3% in palliative chemotherapy, 14.3% in palliative radiotherapy and 13.4% in supportive care.


Distant failure is the predominant pattern of relapse seen in patients undergoing radiochemotherapy for locally advanced cervical cancer. Well-selected single-site relapses treated with surgery or chemotherapy plus radiation can have good post-relapse survival.


Relapse Cervix Radiotherapy 


Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Sreedevi A, Javed R, Dinesh A. Epidemiology of cervical cancer with special focus on India. Int J Womens Health. 2015;7:405–14.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Landoni F, Maneo F, Colombo A, Placa F, Milani R, Perego P, et al. Randomized study of radical surgery versus radiotherapy for stage Ib–IIa cervical cancer. Lancet. 1997;350(9077):535–40.CrossRefGoogle Scholar
  3. 3.
    Vale C, Tierny JF, Stewart LA, Brady M, Dinshaw K, Jakobsen A, et al. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26(35):5802–12.CrossRefGoogle Scholar
  4. 4.
    Liu R, Wang X, Tian JH, Yang K, Wang J, Jiang L, et al. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer. Cochrane Database Syst Rev. 2014;7(10):CD007563.Google Scholar
  5. 5.
    Sturdza A, Potter R, Fokdal LU, Haie-Meder C, Tan LT, Mazeron R, et al. Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol. 2016;120(3):428–33.CrossRefGoogle Scholar
  6. 6.
    Hong JH, Tsai CS, Chang JT, Wang CC, Lai CH, Lee SP, et al. The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41(4):823–30.CrossRefGoogle Scholar
  7. 7.
    Sommers GM, Grigsby PW, Perez CA, Camel HM, Kao MS, Galakatos AE, et al. Outcome of recurrent cervical carcinoma following definitive irradiation. Gynecol Oncol. 1989;35(2):150–5.CrossRefGoogle Scholar
  8. 8.
    Hong JH, Tsai CS, Lai CH, Chang TC, Wang CC, Chou HH, et al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60(1):249–57.CrossRefGoogle Scholar
  9. 9.
    Mabuchi S, Isohashi F, Yoshioka Y, Temma K, Takeda T, Yamamoto T, et al. Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy. Int J Gynecol Cancer. 2010;20(5):834–40.CrossRefGoogle Scholar
  10. 10.
    Eralp Y, Saip P, Sakar B, Kucucuk S, Aydiner A, Dincer M, et al. Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix. Int J Gynecol Cancer. 2003;13(4):497–504.CrossRefGoogle Scholar
  11. 11.
    Long HJ 3rd. Management of metastatic cervical cancer: review of the literature. J Clin Oncol. 2007;25(20):2966–74.CrossRefGoogle Scholar
  12. 12.
    Coleman RL, Keeney ED, Freedman RS, Burke TW, Eifel PJ, Rutledge FN. Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol. 1994;55(1):29–35.CrossRefGoogle Scholar
  13. 13.
    Jeon W, Koh HK, Kim HJ, Wu HG, Kim JH, Chung HH. Salvage radiotherapy for lymph node recurrence after radical surgery in cervical cancer. J Gynecol Oncol. 2012;23(3):168–74.CrossRefGoogle Scholar
  14. 14.
    Legge F, Chiantera V, Macchia G, Fagotti A, Fanfani F, Ercoli A, et al. Clinical outcome of recurrent locally advanced cervical cancer (LACC) submitted to primary multimodality therapies. Gynecol Oncol. 2015;138(1):83–8.CrossRefGoogle Scholar
  15. 15.
    Elit L, Fyles AW, Oliver TK, Devries-Aboud MC, Fung-Kee-Fung M. Follow-up for women after treatment for cervical cancer. Curr Oncol. 2010;17(3):65–9.CrossRefGoogle Scholar
  16. 16.
    Lanceley A, Fiander A, McCormack M, Bryant A. Follow-up protocols for women with cervical cancer after primary treatment. Cochrane Database Syst Rev. 2013;11(11):CD008767.Google Scholar
  17. 17.
    Lawhead RAJ, Clark DG, Smith DH, Pierce VK, Lewis JLJ. Pelvic exenteration for recurrent or persistent gynecologic malignancies: a 10-year review of the memorial sloan-kettering cancer center experience (1972–1981). Gynecol Oncol. 1989;33(3):279–82.CrossRefGoogle Scholar
  18. 18.
    Kundargi RS, Guruprasad B, Hanumantappa N, Rathod PS, Devi UK, Bafna UD. The role of surgery in locally advanced carcinoma of cervix after sub-optimal chemoradiation: Indian scenario. South Asian J Cancer. 2013;2(3):137–9.CrossRefGoogle Scholar
  19. 19.
    Ota T, Takeshima N, Tabata T, Hasumi K, Takizawa K. Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy. Br J Cancer. 2008;99(8):1216–20.CrossRefGoogle Scholar
  20. 20.
    Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340(15):1154–61.CrossRefGoogle Scholar
  21. 21.
    Mahantshetty U, Kalyani N, Engineer R, Chopra S, Jamema S, Ghadi Y, et al. Reirradiation using high-dose-rate brachytherapy in recurrent carcinoma of uterine cervix. Brachytherapy. 2014;13(6):548–53.CrossRefGoogle Scholar
  22. 22.
    Mabuchi S, Takahashi R, Isohashi F, Yokoi T, Okazawa M, et al. Reirradiation using high-dose-rate interstitial brachytherapy for locally recurrent cervical cancer: a single institutional experience. Int J Gynecol Cancer. 2014;24(1):141–8.CrossRefGoogle Scholar
  23. 23.
    Grigsby PW, Vest ML, Perez CA. Recurrent carcinoma of the cervix exclusively in the paraaortic nodes following radiation therapy. Int J Radiat Oncol Biol Phys. 1994;28(2):451–5.CrossRefGoogle Scholar
  24. 24.
    Chou HH, Wang CC, Lai CH, Hong JH, Ng KK, Chang TC, et al. Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma. Int J Radiat Oncol Biol Phys. 2001;51(2):442–8.CrossRefGoogle Scholar
  25. 25.
    Singh AK, Grigsby PW, Rader JS, Mutch DG, Powell MA. Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence. Int J Radiat Oncol Biol Phys. 2005;61(2):450–5.CrossRefGoogle Scholar
  26. 26.
    Kim JS, Kim JS, Kim SY, Kim KH, Cho MJ. Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2003;55(5):1247–53.CrossRefGoogle Scholar
  27. 27.
    Niibe Y, Kenjo M, Kazumoto T, Michimoto K, Takayama M, Yamauchi C, et al. Multi-institutional study of radiation therapy for isolated para-aortic lymph node recurrence in uterine cervical carcinoma: 84 subjects of a population of more than 5000. Int J Radiat Oncol Biol Phys. 2006;66(5):1366–9.CrossRefGoogle Scholar

Copyright information

© Association of Gynecologic Oncologists of India 2019

Authors and Affiliations

  • Ajay Sasidharan
    • 1
  • Umesh M. Mahantshetty
    • 1
    Email author
  • Lavanya Gurram
    • 1
  • Supriya Chopra
    • 1
  • Reena Engineer
    • 1
  • Amita Maheshwari
    • 2
  • Sudeep Gupta
    • 3
  • Kedar Deodhar
    • 4
  • Venkatesh Rangarajan
    • 5
  • Meenakshi Thakur
    • 6
  • Shyam Kishore Shrivastava
    • 1
  1. 1.Department of Radiation OncologyTata Memorial HospitalParel, MumbaiIndia
  2. 2.Department of Surgical OncologyTata Memorial HospitalParel, MumbaiIndia
  3. 3.Department of Medical OncologyTata Memorial HospitalParel, MumbaiIndia
  4. 4.Department of PathologyTata Memorial HospitalParel, MumbaiIndia
  5. 5.Department of Nuclear MedicineTata Memorial HospitalParel, MumbaiIndia
  6. 6.Department of RadiologyTata Memorial HospitalParel, MumbaiIndia

Personalised recommendations